Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for VAX-A1 (Protein Vaccine) in Group A Streptococcal Infection. The expected timing is based on the latest available company guidance and may change.
02/24/26:- Plan to initiate adult Ph1 VAX-A1 safety and tolerability trial in Australia during 2026. 05/06/26:- Plan refined to initiate adult Phase 1 VAX-A1 trial in Australia in mid-2026. 06/02/26:- First participant dosed in adult Ph1 NCT07616934. Topline data expected H2 2027. 08/05/26:- All Stage 1 participants received first dose. Ph1 topline data H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.